(lp0
S'Market: The Morgan Stanley Has $42794000 Position in United Therapeutics ... Petro Global News 24 - Jan 27, 2017 A number of other large investors have also recently made changes to their positions in UTHR. Daiwa Securities Group Inc. raised its position in shares of United Therapeutics Corporation by 16.7% in the second quarter. Daiwa Securities Group Inc. now&nbsp;...'
p1
aS'Market: The United Therapeutics Corporation  Position Maintained by ... Petro Global News 24 - Jan 26, 2017 Several other large investors have also added to or reduced their stakes in the company. AQR Capital Management LLC raised its stake in United Therapeutics Corporation by 21.2% in the second quarter. AQR Capital Management LLC now owns 1,584,113&nbsp;...'
p2
aS'Market: The United Therapeutics Corp.  Stake Reduced by Sumitomo Mitsui ... Petro Global News 24 - Feb 2, 2017 A number of other hedge funds and other institutional investors also recently bought and sold shares of UTHR. Daiwa Securities Group Inc. raised its position in United Therapeutics Corp. by 16.7% in the second quarter. Daiwa Securities Group Inc. now ...'
p3
aS'Market: The New Amsterdam Partners LLC NY Has $5480000 Stake in United ... Petro Global News 24 - Feb 3, 2017 A number of other institutional investors have also added to or reduced their stakes in UTHR. Bridgewater Wealth &amp; Financial Management LLC raised its stake in United Therapeutics Corporation by 6.4% in the third quarter. Bridgewater Wealth &amp; Financial&nbsp;...'
p4
aS'United Therapeutics loses challenge to its drug patent Washington Business Journal - Apr 3, 2017 Silver Spring-based biotech United Therapeutics Corp.  lost a recent challenge to one of its lead patents for its flagship drugs.SteadyMed Wins Patent Challenge  - InvestopediaPTAB Invalidates Patent For Hypertension Treatment - Law360 '
p5
aS'United Therapeutics Tanks, Remodulin Pump Launch Delayed Zacks.com - Apr 4, 2017 United Therapeutics Corporation  shares plunged around 9% on Monday after the company announced that regulatory issues will delay the planned U.S.United Therapeutics Announces Regulatory Delays For Remosynch Implantable Pump - Yahoo FinanceWhy General Motors Company , Acorda Therapeutics Inc  and United ... - Investorplace.com'
p6
aS'Respira Therapeutics Announces Collaboration with United Therapeutics to Treat ... PR Newswire  - Apr 12, 2017 ... Respira Therapeutics, Inc., a privately held pharmaceutical company developing innovative inhaled therapies to treat pulmonary hypertension and other pulmonary diseases, has entered into a strategic collaboration with United Therapeutics ...'
p7
aS'United Therapeutics Falls After US Launch Of RemoSynch Gets Delayed Benzinga - Apr 3, 2017 Investors are exiting the issue following the announcement that the U.S. launch of RemoSynch will be delayed due to regulatory delays.'
p8
aS'United Therapeutics Announces Decision From Patent Trial And Appeal Board And ... PR Newswire  - Mar 31, 2017 SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., March 31, 2017 /PRNewswire/ -- United Therapeutics Corporation  today announced that the U.S.SteadyMed Receives Favorable Ruling in Inter Partes Review against United ... - GlobeNewswire '
p9
aS'United Therapeutics loses treprostinil patent challenge; shares slip 2% Seeking Alpha - Mar 31, 2017 United Therapeutics  moves into the red after the U.S. Patent Trial and Appeal Board  rules that all the claims of U.S.'
p10
a.